Trial Profile
A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Eftrenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Therapeutic Use
- Acronyms B-SURE
- Sponsors Swedish Orphan Biovitrum
- 31 Jan 2024 According to Sobi media release, company will present secondary paediatric analysis data from B-MORE Study at the 17th European Association of Haemophilia and Allied Disorders (EAHAD) conference in Frankfurt from 6-9 February 2024.
- 11 May 2022 Status changed from active, no longer recruiting to completed.
- 21 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.